We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 58% below its sector, cheaper than its peers on earnings.
Founded in 1998 and headquartered in Chuncheon, South Korea, Boditech Med Inc. specializes in the development of in-vitro diagnostic solutions and reagents. The company's diverse product portfolio includes a range of advanced immunoassay analyzers designed to quantify analytes in various biological samples like blood, urine, and other body fluids. Key offerings include the ichroma II, an automated or semi-automated system for precise analyte measurement; AFIAS-6 and AFIAS-1, automated fluorescent immunoassay systems also designed for accurate quantification of targeted analytes; and the ichroma-50, an automatic immunoassay analyzer that determines analyte concentrations in bodily fluids. Additionally, the ichroma M2 is a portable analyzer suited for centralized hospital laboratories and physician's clinics, compatible with in-vitro diagnostic immunofluorescent assay kits for screening, monitoring, and routine examinations. Beyond these, Boditech Med also provides specialized diagnostic instruments such as the Ichroma TRIAS Reader, which measures targeted analyte concentration from diverse samples including blood, nasal, and nasopharyngeal swabs; the Hemochroma PLUS for quantitative total hemoglobin testing in blood; the i-chamber, an auxiliary component for ichroma systems; and the HandyRay, an innovative laser device facilitating needle-free capillary blood sampling. These diagnostic solutions address a broad spectrum of medical fields, including cardiac health, oncology, diabetes management, hormone analysis, infection, infectious diseases, gastrointestinal issues, and rheumatoid arthritis. Boditech Med Inc. distributes its products globally through a network of approximately 100 sales agencies.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 206640.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.